Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has completed cohort dosing of both male and female subjects in the Phase 1/2 UTI/Urosepsis clinical trial evaluating its experimental compound RECCE® 327 (R327) at faster infusion rates.
The company, which is developing a novel class of synthetic anti-infectives, reported the results showing a robust safety profile for R327 when administered at a faster infusion rate of 30 minutes of 3,000mg via intravenous administration.
The independent safety committee reviewing the complete cohort dosing data is expected to give its recommendation for the trial to proceed, with subject recruitment for the next cohort underway.
Potential treatment option
Recce chief executive officer James Graham said: “We are pleased to see R327 administered at a faster infusion rate of 3,000mg, reinforcing R327’s safety profile among male and female subjects.
“These results further support R327’s potential as a treatment option, positioning it as a therapy for patients suffering from UTI/Urosepsis, which is responsible for about 30% of all sepsis infections.”
Unmet medical need
UTIs are responsible for about 30% of all sepsis infections, defined as ‘Urosepsis’.
R327’s potential as a treatment option across the patient's infectious disease journey positions it for therapy in this area of unmet medical need.
R327 is an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms.